CHRISTINA LOPES M.A.: Founder & ceo
Christina Lopes is a co-founder of The One Health Company. Previously, Christina was a Managing Director of Cerberus Capital Management and since Cerberus, Christina has been working on deals in the innovation space including Biotech for AIMCO. Christina has served on the Board of International Planned Parenthood for the Western Hemisphere, participated in The United Nations Commission for the Status of Women, and lectured at Columbia University. She was selected by the World Economic Forum as a Young Global Leader in March 2010. This honor is bestowed each year to recognize the most distinguished young leaders nominated below the age of 40 from around the world. Christina was also honored a Rising Talent by the Women’s Forum in 2014. She holds a B.A. from the University of Massachusetts, a Masters in International and Political Affairs from Columbia University, and Doctoral Coursework in Ethics at Princeton University.
Benjamin Lewis: FOUNDER & Chief operating officer
Benjamin Lewis is an animal health visionary, proud pet parent (whose dog participated in a trial), a clinical trial participant and former Olympic Athlete. Today, Ben is the Co-Founder and COO of The One Health Company, an innovative contract-research organization exclusively utilizing spontaneous disease models in companion animals. Formerly, Ben was the Co-Founder and CEO of 4Vets, the largest B2B distributor of animal health products in Brazil. Ben also represented the United States in the 2004 Olympics in Athens, Greece, where he served as Captain of the K4. Ben studied Bioengineering at Dartmouth College where he was inducted in the Dartmouth Hall of Fame (Wearer of the Green). Ben also studied Veterinary Medicine at the University of Pennsylvania School of Veterinary Medicine, and Health Care Management at The Wharton School of Business.
Franca S. Angeli, M.D., Ph.D.: Chief medical officer
Biomedical Researcher formerly at the Texas Heart Institute (UT-THI), UCSF and Penn Med with over 15 years experience in R&D. Over 50 trials performed. Expertise in product development and support, designing and conducting pre-clinical and clinical studies; data collection, statistical analysis and database management; writing, submission, and revision of several pre-clinical and clinical protocol, grants, manuscripts, book chapters, regulatory documents; understanding and applying regulatory, ethical and institutional policies and procedures; supervising CRC’s work in clinical trials; PI and Co-PI in clinical studies; and administrative management including purchasing, budgeting, safety and certifications, interaction with sponsors and donors, web management, personnel supervision and training. Recognized ability to multi-task and manage several projects in parallel, paying attention to detail and to forge cross-functional working relationships with internal teams and external project partners.
Ravi Tolwani, D.V.M., Ph.D.: Chief Scientific Officer
Dr. Tolwani is the former President of the American College of Laboratory Animal Medicine (ACLAM), and has overseen Rockefeller University’s Comparative Bioscience Center’s (CBC) since 2007. From 1994 to 2007, he served on the faculty of the Stanford University School of Medicine, where his laboratory focused on understanding the molecular mechanisms of brain plasticity. Dr. Tolwani holds a doctorate of veterinary medicine from Auburn University, in Alabama. After two years in private practice, treating pets in Nashville, Tennessee, he turned to research, completing a Ph.D. in cellular and molecular pathology and postdoc residency in laboratory animal/comparative medicine at the University of Alabama, Birmingham. For his research, he developed a mouse model to study a common illness in humans associated with an enzyme deficiency in fat metabolism. Dr. Tolwani later earned a master of science in management degree, an M.B.A. equivalent for mid-career professionals, at the Stanford Graduate School of Business. Ravi is an industry insider pushing animal models into the 21st Century.
JONATHAN LUSTGARTEN VMD PhD MS: CHIEF TECHNOLOGY OFFICER
Dr. Lustgarten brings years of expertise in veterinary medicine, veterinary clinical trials, and biomedical informatics to the One Health Team. Jon is a MS in Bioinformatics and a PhD in Biomedical Informatics from University of Pittsburgh Medical School, BS in computational biology and bio-organic chemistry from Carnegie Mellon University, and a VMD in veterinary medicine from University of Pennsylvania School of Veterinary Medicine. Jon is President-elect of the Association of Veterinary Informatics. He has experience coordinating and managing a network of 168 veterinarians, deploying various technology across large networks, advanced genetics and proteomics data mining using artificial intelligence, coordinating and managing data acquisition and validation for more than 15 clinical studies, and financial analysis and operations of hospitals and clinical studies on both the veterinary hospital and clinical provider/researcher sides. He has experience developing a veterinary world-wide electronic medical record system to use for natural disasters as well as expertise in human electronic record system integration in one of the largest health networks in the country. He is responsible for planning and overseeing development of the 1Healthomics Platform.
Rick winneker: BUSINESS DEVELOPMENT
Dr. Winneker is a life science executive and discovery research subject matter expert with experience in all phases of research and development who has led several pharmaceutical research organizations that resulted in 14 compounds being delivered to the development pipeline and four registered products. Prior to One Health, Rick was Senior Vice President of Research at the Leukemia & Lymphoma Society, building and leading a research group focused on improving the standard of care and accelerating cures for patients with blood cancers. Dr. Winneker brings 30 years of experience, specializing in drug discovery and development, and life sciences research and organizational strategic planning. He also worked for nearly 15 years at Wyeth Research, spearheading a drug discovery group. Dr. Winneker is known for developing high performance teams of investigators; building trusted and collaborative partnerships. Dr. Winneker earned a Bachelor of Science degree from Penn State University, a Master of Science degree in physiology from University of Illinois at Urbana-Champaign, and a PhD in anatomy from the University of Minnesota.
Bob Palladino: CFO
Bob is a Senior Executive with 35 years of global strategic and operating experience in Drug Discovery, Genomic Sequencing/Interpretation, Social Media and Registry Patient Data, Stem Cell, Medical Devices/Delivery Systems, Monitoring/Detection, Laparoscopy Procedure Systems, Gynecology, and Oncology. Bob has served as CFO for Claritas Genomics, BioNevia, Corrona, PatientsLikeMe.
Mark Anderson, Ph.D.: Research & Development Consultant
Dr. Mark Anderson is a cancer biologist and drug developer with over 20 years of experience in the biotechnology and pharmaceutical industries. He has led drug discovery teams focused on the preclinical development of biologically based therapeutics for cancer that advanced multiple novel agents from discovery to clinical testing. He received his Ph.D. in Biological Chemistry from the University of Michigan in Ann Arbor and conducted his postdoctoral training at Merck Research Laboratories in West Point, Pennsylvania. Dr. Anderson spent several years in the biotechnology industry discovering and developing innate immune stimulants and anti-cancer agents at Magainin Pharmaceuticals, followed by 15 years at Johnson & Johnson leading teams developing anti-cancer biologics, most recently as Scientific Director of Oncology Research at Janssen Pharmaceuticals. He has published numerous peer-reviewed journal articles, book chapters, and patents in the areas of transcriptional control, innate immunity, cancer biology, and biologic cancer therapeutics. Dr Anderson’s expertise includes strategic R&D and business planning and the technical development of antibodies, antibody drug conjugates, novel biologic scaffolds, immuno-oncology agents, and bispecific antibodies for the treatment of cancer.
And many more...
The team at The One Health Company includes a number of researchers, vets, scientists, and animal lovers who share one common interest: advancing standards of care for our peers and companion animals.